Get started
Author

Yuka Iijima‐Yamashita

Observed names: Y. Iijima-Yamashita, Yuka Iijima-Yamashita
ORCID: 0000-0003-3954-258X
Observed ORCID: 0000-0003-3954-258X
OpenAlex ID: A5049685204
Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation
2017 · Tetsuichi Yoshizato, Yasuhito Nannya, et al. · Blood · 355
Germ line DDX41 mutations define a unique subtype of myeloid neoplasms
2022 · Hideki Makishima, Ryunosuke Saiki, et al. · Blood · 152
Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations
2021 · Takahiko Yasuda, Masashi Sanada, et al. · Blood · 57
Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia
2020 · Hiroo Ueno, Kenichi Yoshida, et al. · Blood Advances · 56
Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study
2018 · Akira Shimada, Yuka Iijima-Yamashita, et al. · International Journal of Hematology · 32
Prognostic impact of minimal disseminated disease and immune response to NPM-ALK in Japanese children with ALK-positive anaplastic large cell lymphoma
2017 · Yuka Iijima-Yamashita, Tetsuya Mori, et al. · International Journal of Hematology · 22
JCCG ALL-B12: Evaluation of Intensified Therapies With Vincristine/Dexamethasone Pulses and Asparaginase and Augmented High-Dose Methotrexate for Pediatric B-ALL
2024 · Motohiro Kato, Yasuhiro Okamoto, et al. · Journal of Clinical Oncology · 19
Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia
2017 · Yachiyo Kuwatsuka, Daisuke Tomizawa, et al. · International Journal of Hematology · 19
Monitoring of fusion gene transcripts to predict relapse in pediatric acute myeloid leukemia
2017 · Hidemasa Matsuo, Yuka Iijima‐Yamashita, et al. · Pediatrics International · 18
Multiplex fusion gene testing in pediatric acute myeloid leukemia
2017 · Yuka Iijima‐Yamashita, Hidemasa Matsuo, et al. · Pediatrics International · 17
High-dose cytarabine induction therapy and flow cytometric measurable residual disease monitoring for children with acute myeloid leukemia
2023 · Daisuke Tomizawa, Jun Matsubayashi, et al. · Leukemia · 9
PDF
Clinical Impacts of Germline DDX41 Mutations on Myeloid Neoplasms
2020 · Hideki Makishima, Yasuhito Nannya, et al. · Blood · 8
High IL2RA/CD25 expression is a prognostic stem cell biomarker for pediatric acute myeloid leukemia without a core‐binding factor
2023 · Takahiro Aoki, Norio Shiba, et al. · Pediatric Blood & Cancer · 7
PDF
Bortezomib-containing therapy in Japanese children with relapsed acute lymphoblastic leukemia
2019 · Daisuke Hasegawa, Yuri Yoshimoto, et al. · International Journal of Hematology · 7
Application of prime editing system to introduce TP53 R248Q hotspot mutation in acute lymphoblastic leukemia cell line
2024 · Thao Nguyen, Tomomi Aida, et al. · Cancer Science · 6
Pediatric acute myeloid leukemia co‐expressing FLT3/ITD and NUP98/NSD1 treated with gilteritinib plus allogenic peripheral blood stem cell transplantation: A case report
2021 · Takanari Abematsu, Takuro Nishikawa, et al. · Pediatric Blood & Cancer · 6
Clinicopathological features and prognostic significance of programmed death ligand 1 in pediatric ALK-positive anaplastic large cell lymphoma: results of the ALCL99 treatment in Japan
2021 · Hideto Iwafuchi, Atsuko Nakazawa, et al. · Human Pathology · 4
A Nationwide Clinical Trial ALL-B12: An Optimized Therapy for Pediatric B-Precursor Acute Lymphoblastic Leukemia with Excellent Overall Survival and Minimal Non-Relapse Mortality: A Report from the Japan Children's Cancer Group
2023 · Motohiro Kato, Yasuhiro Okamoto, et al. · Blood · 3
Phase 2 study of combination chemotherapy with bortezomib in children with relapsed and refractory acute lymphoblastic leukemia
2023 · Naoyuki Miyagawa, Hiroaki Goto, et al. · International Journal of Hematology · 3
P741: Ddx41 Mutations Define a Unique Subtype of Myeloid Neoplasms.
2022 · H. Makishima, R. Saiki, et al. · HemaSphere · 3
Safety and efficacy of arsenic trioxide in intensification therapy for newly diagnosed childhood acute promyelocytic leukemia: results from the JPLSG AML-P13 study
2025 · Hiroyuki Takahashi, Shiro Tanaka, et al. · International Journal of Hematology · 2
PPM1D and DNMT3A Mutations in Myelodysplasia and Clonal Hematopoiesis
2019 · Masanori Motomura, Yoshikage Inoue, et al. · Blood · 2
Combined Tyrosine Kinase Inhibitors and Chemotherapy Based on Minimal Residual Disease in Children With Ph + Acute Lymphoblastic Leukemia: A Phase 2 Single‐Arm Trial, JCCG ALL‐Ph13
2026 · Atsushi Sato, Yuichi Kodama, et al. · Pediatric Blood & Cancer · 1
Prognostic value of minimal disseminated disease assessed using digital polymerase chain reaction for 3'ALK assays in pediatric anaplastic lymphoma kinasepositive anaplastic large cell lymphoma
2023 · Reiji Fukano, Yuka Iijima-Yamashita, et al. · Haematologica · 1
PDF
Safety and Efficacy of Arsenic Trioxide in the Treatment of Newly Diagnosed Pediatric Acute Promyelocytic Leukemia: Results from the JPLSG AML-P13 Study
2022 · Hiroyuki Takahashi, Shiro Tanaka, et al. · Blood · 1
Works count: 43
Citation count: 813
H-index: 10
I10-index: 10
Year
Topic
Type